Antiangiogenic therapy of colorectal cancer: State of the art, challenges and new approaches

International Journal of Biological Markers

Volumn 27, Issue 4, 2012, Pages

  Sarmiento, Roberta ^a   Longo, Raffaele ^a   Gasparini, Giampietro ^a  

^a SAN FILIPPO NERI HOSPITAL   (Italy)

Author keywords

Angiogenesis; Bevacizumab; Colorectal cancer

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CAPECITABINE PLUS OXALIPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; MITOMYCIN; OXALIPLATIN; VASCULOTROPIN RECEPTOR;

ADJUVANT THERAPY; ANTIANGIOGENIC THERAPY; ARTICLE; BLEEDING; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; DIGESTIVE SYSTEM PERFORATION; DRUG DOSE REDUCTION; HUMAN; LIVER METASTASIS; METASTASIS; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTUM CANCER; THROMBOEMBOLISM; TOXICITY; WOUND HEALING;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84872871235     PISSN: 03936155     EISSN: 17246008     Source Type: Journal    
DOI: 10.5301/JBM.2012.10441     Document Type: Article

References (58)

1. http://seer.cancer.gov/csr/1975_2009pops09 [AUTHORS: Please check this link, as the page cannot be found]
2. Hurwitz H, Feherenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
3. Rothenberg ML, Oza AM, Bigelow RH, et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 2003; 21: 2059-2069.
4. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947.
5. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combination in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22: 23-30.
6. Cunningham D, Pyrhönen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352: 1413-1418.
7. Saltz LB, Coz JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000; 343: 905-914.
8. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (folfox4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group study E3200. J Clin Oncol 2007; 25: 1539-1544.
9. Ziras N, Polyzos A, Kakolyris S, et al. CAPIRI (capecitabine, irinotecan) + bevacizumab vs FOLFIRI (folinic acid, 5 fluorouracil, irinotecan) + bevacizumab for the treatment of patients with metastatic colorectal cancer (mCRC): interim analysis for safety of a randomized phase III trial. J Clin Oncol 2008; 26(suppl): abstr 15008.
10. Avastin product information. Available from: http://www.gene.com/gene/products/information/pdf/avastin-prescribing.pdf. Accessed 28 May 2011.
11. Cao Y, Arbiser J, D'Amato RJ, et al. Forty-year journey of angiogenesis translational research. Sci Transl Med 2011; 3: 114rv3.
12. Sitohy B, Nagy JA, Jaminet SC, Dvorak HF. Tumor-surrogate blood vessel subtypes exhibit differential susceptibility to anti-VEGF therapy. Cancer Res 2011; 71: 7021-8.
13. Neugut AI, Becker DJ, Buono D, Kershenbaum A, Herschman DL. Off-label approved use of bevacizumab in elderly patients with colon cancer. J Clin Oncol 2010; 28 (suppl): abstr e14038.
14. Chong G, Tebbutt NC. Using bevacizumab with different chemotherapeutic regimens in metastatic colorectal cancer: balancing utility with low toxicity. Ther Advanc Med Oncol 2010; 2: 309-17.
15. Price TJ, Zannino D, Wilson K, et al. Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomized controlled trial of capecitabine, bevacizumab and mitomycin C. Ann Oncol 2012; 23: 1531-1536.
16. Venderbosch S, Doornebal J, Teerenstra S, Lemmens W, Punt CJ, Koopman M. Outcome of first-line systemic treatment in elderly compared to younger patients with metastatic colorectal cancer: a retrospective analysis of the CAIRO and CAIRO2 studies of the Dutch Colorectal Cancer Group (DCCG). Acta Oncol 2012; 51: 831-839.
17. Hurwitz HI, Yi J, Ince W, Novotny WF, Rosen O. The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer. Oncologist 2009; 14: 22-28.
18. Cassidy J, Clarke S, Diaz-Rubio E, et al. XELOX vs FOLFOX- 4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. Br J Cancer 2011; 105: 58-64.
19. Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009; 360: 563-572.
20. Hecht JR, Mitchell E, Chidiac T, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009; 27: 672-80.
21. Van Cutsem E, Nowacki M, Lang I, et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL STUDY. J Clin Oncol 2007; 25(suppl): abstr 4000.
22. Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009; 27: 663-671.
23. Maughan TS, Adams RA, Smith CG, et al. Addition of cetuximab to oxaliplatin-based first-line combinations chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011; 377: 2103-2114.
24. Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010; 28: 4697-4705.
25. Wong R, Cunningham D, Barbachano Y, et al. A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. Ann Oncol 2011; 22: 2042-2048.
26. Hurwitz HI, Fehrenbacher L, Haisworth JD, et al. Bevacizumab in combination with fluorouracil and leucovorin: an enactive regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005; 23: 3502-3508.
27. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as firstline therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26: 2013-2019.
28. Tebbutt NC, Wilson K, Gebski VJ, et al. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group randomized phase III MAX Study. J Clin Oncol 2010; 28: 3191-3198.
29. Van Cutsem E, Rivera F, Berry S, et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 2009; 20: 1842-1847.
30. Kozloff M, Yood MU, Berlin J, et al. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal study: the BriTE observational cohort study. Oncologist 2009; 14: 862-870.
31. Bekaii-Saab TS, Grothey A, Bendell JC, et al. Effectiveness and safety of second-line (2L) irinotecan- and oxaliplatin- based regimens after first-line (1L) bevacizumab (BV)- containing treatment (tx) for metastatic colorectal cancer (mCRC): results from the ARIES observational cohort study. J Clin Oncol 2012; 4(SUPPL): abstr 535.
32. Allegra CJ, Yothers G, O'Connell J, et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol 2011; 29: 11-16.
33. De Gramont A, Van Cutsem E, Tabernero J, et al. AVANT: Results from a randomized, three-arm multinational phase III study to investigate bevacizumab with either XELOX or FOLFOX4 versus FOLFOX4 alone as adjuvant treatment for colon cancer. J Clin Oncol 2011; 29(suppl): abstr 362.
34. Quasar Collaborative Group; Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, Kerr DJ. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 2007; 370: 2020-2029.
35. ECOG-E 5202, NCT 00217737. Phase III randomized study of oxaliplatin, leucovorin calcium, and fluorouracil with or without bevacizumab in patients with resected stage II colon cancer and at high risk for recurrence based on molecular markers. http://www.clinicaltrials.gov/show/NCT00217737.
36. Willett CG, Duda DG, di Tomaso E, et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol 2009; 27: 3020-3026.
37. Crane CH, Eng C, Feig BW, et al. Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2010; 76: 824-830.
38. Velenik V, Ocvirk J, Music M, et al. Neoadjuvant capecitabine, radiotherapy, and bevacizumab (CRAB) in lo cally advanced rectal cancer: results of an open-label phase II study. Radiation Oncol 2011; 6: 105.
39. Koukourakis MI, Giatromanolaki A, Tsoutsou P, et al. Bevacizumab, capecitabine, amifostine, and preoperative hypofractionated accelerated radiotherapy (HypoArc) for rectal cancer: a phase II study. Int J Radiat Oncol Biol Phys 2011; 80: 492-498.
40. Resch G, De Vries A, Ofner D, et al. Preoperative treatment with capecitabine, bevacizumab, and radiotherapy for primary locally advanced rectal-cancer--a two stage phase II clinical trial. Radiother Oncol 2012; 102: 10-13.
41. Dipetrillo T, Pricolo V, Lagares-Garcia J, et al. Neoadjuvant bevacizumab, oxaliplatin, 5-fluorouracil, and radiation for rectal cancer. Int J Radiat Oncol Biol Phys 2012; 82: 124-129.
42. Spigel DR, Bendell JC, McCleod M, et al. Phase II study of bevacizumab and chemoradiation in the preoperative or adjuvant treatment of patients with stage II/III rectal cancer. Clin Colorectal Cancer 2012; 11: 45-52.
43. Kennecke H, Berry S, Wong R, et al. Pre-operative bevacizumab, capecitabine, oxaliplatin and radiation among patients with locally advanced or low rectal cancer: a phase II trial. Eur J Cancer 2012; 48: 37-45.
44. Gasparini G, Torino F, Ueno T, et al. A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer. Angiogenesis 2012; 15: 141-150.
45. Martinez Villacampa M, Capdevila J, Manzano JL, et al. A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer. J Clin Oncol 2012; 30(suppl): abstr 3571.
46. Nogué M, Salud A, Vicente P, et al. Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabine-based CRT in magnetic resonance imagingdefined poor-prognosis locally advanced rectal cancer: the AVACROSS study. Oncologist 2011; 16: 614-620.
47. Kumar R, Knick VB, Rudolph SK, et al. Pharmacokineticpharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 2007; 6: 2012-2021.
48. Longo R, Gasparini G. Challenges for patient selection with VEGF inhibitors. Cancer Chemother Pharmacol 2007; 60: 151-170.
49. Longo R, Gasparini G. Anti-VEGF therapy: the search for clinical biomarkers. Expert Rev Mol Diagn 2008; 8: 301-314.
50. Xu CF, Bing NX, Ball HA, et al. Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes. J Clin Oncol 2011; 29: 2557-2564.
51. Abajo A, Boni V, Lopez I, et al. Identification of predictive circulating biomarkers of bevacizumab-containing regimen efficacy in pre-treated metastatic colorectal cancer patients. Br J Cancer 2012; 107: 287-290.
52. Manzoni M, Mariucci S, Delfanti S, et al. Circulating en dothelial cells and their apoptotic fraction are mutually independent predictive biomarkers in bevacizumab-based treatment for advanced colorectal cancer. J Cancer Res Clin Oncol 2012; 138: 1187-1196.
53. Pohl A, El-Khoueiry A, Yang D, et al. Pharmacogenetic profiling of CD 133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy. Pharmacogenomics J 2012; doi: 10.1038/ tpj.2011.61. [Epub ahead of print].
54. Hansen TF, Christensen Rd, Andersen RF, Garm Spindler KL, Johnsson A, Jakobsen A. The predictive value of single nucleotide polymorphisms in the VEGF system to the efficacy of first-line treatment with bevacizumab plus chemotherapy in patients with metastatic colorectal cancer: results from the Nordic ACT trial. Int J Colorectal Dis 2012; 27: 715-720.
55. Van Cutsem E, Lang I, Folprecht G, et al. Cetuximab plus FOLFIRI in the treatment of metastatic colorectal cancer (mCRC): the influence of KRAS and BRAF biomarkers on outcome: updated data from the CRYSTAL trial. J Clin Oncol 2010; 28(suppl), abstr 281.
56. Toffoli G, Cecchin E, Gasparini G, et al. Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer. J Clin Oncol 2010; 28: 866-871.
57. Zulato E, Curtarello M, Nardo G, Indraccolo S. Metabolic effects of anti-angiogenic therapy in tumors. Biochimie 2012; 94: 925-931.
58. Nardo G, Favaro E, Curtarello M, et al. Glycolytic phenotype and AMP kinase modify the pathologic response of tumor xenografts to VEGF neutralization. Cancer Res 2011; 71: 4214-4225.